EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

EU authorization of Rinvoq (upadacitinib) by AbbVie Deutschland for multiple inflammatory indications including rheumatoid arthritis, psoriatic arthritis, axial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis
• Crohn Disease
• Dermatitis Atopic
• Giant Cell Arteritis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Spondylitis Ankylosing
• Ulcerative Colitis

Drugs mentioned

• RINVOQ (Upadacitinib)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;Arthritis, Psoriatic;Axial Spondyloarthritis;Spondylitis, Ankylosing;Giant Cell Arteritis;Dermatitis, Atopic;Colitis, Ulcerative;Crohn Disease. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 04/06/2026